Ireland
--:--IST
Active, not recruiting Not applicable

PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial

NCT05466838 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2023-01-06
Last updated
2024-12-24

Condition(s) studied

Pancreatic Insufficiency

Investigational drug(s) / intervention(s)

PERT at dischargeStandard of Care

PERT at discharge: Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.

Standard of Care: Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.

Study summary

After pancreas surgery, patients may develop pancreatic exocrine insufficiency (PEI). PEI can be treated with oral pancreatic enzyme replacement therapy (PERT). However, the diagnosis of PEI is difficult and the guidelines about when to start PERT after pancreas surgery are conflicting. This pilot study aims to determine the feasibility of implementing a large-scale clinical trial to definitively evaluate if starting PERT immediately after surgery can improve outcomes in patients undergoing pancreas surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adults aged \>18 years 2. Willing and able to provide informed consent and/or have a substitute decision maker (SDM) provide informed consent on behalf of the participant 3. Planned PD for any indication AND, at randomization 4. PD performed 5. Discharge planned within 21 days of surgery Exclusion Criteria: 1. Contraindication to PERT including: 1. Hypersensitivity to porcine protein, pancreatic enzymes or any excipients 2. History of fibrosing colonopathy 3. Unable to tolerate oral medication 2. Current use of PERT OR, at randomization 3. Use of PERT at the time of randomization

Primary outcome measure(s)

  • Proportion of patients screened who consent — Baseline
    Each centre will keep a screening log of all patients who are scheduled to undergo an elective pancreaticoduodenectomy and perform pre-screening to determine eligibility. The number of eligible patients who are approached for and consent to participate, as well as the number of approached eligible patients who decline to participate (and reasons for declining) will be recorded and the proportions will be calculated
  • Proportion of patients screened who meet eligibility criteria — Baseline
    Each centre will keep a screening log of all patients who are scheduled to undergo an elective pancreaticoduodenectomy and perform pre-screening to determine eligibility. The eligibility criteria that are unmet will be recorded, including the additional criteria for randomization. This will be used to calculate proportions.
  • Adherence to PERT — 3 months
    Recorded on participant's medication tracker and calculated as a percentage of expected vs. actual doses taken.
  • Adherence to PERT dosing guidelines — Day 0 (Discharge)
    Review of medical record for appropriate use of PERT dosing guidelines, comparing actual prescription to dosing guideline
  • Adherence to PERT dosing guidelines — 1 month
    Review of medical record for appropriate use of PERT dosing guidelines, comparing actual prescription to dosing guideline
  • Adherence to PERT dosing guidelines — 3 months
    Review of medical record for appropriate use of PERT dosing guidelines, comparing actual prescription to dosing guideline
  • Completeness of dataset — 3 months
    Assessment of completeness of data, loss to follow-up and missing data and reasons for not being able to collect data
  • Resource requirement for definitive trial — Study completion (1.5 years)
    Each site will complete a survey at the end of the trial to report the amount of time spent on study activities

Trial sites (6)

FacilityCityRegionStatus
Hamilton Health Sciences Centre Hamilton Ontario
Kingston General Hospital Kingston Ontario
London Health Sciences Centre London Ontario
The Ottawa Hospital Ottawa Ontario
Sunnybrook Health Sciences Centre Toronto Ontario
University Health Network Toronto Ontario
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05466838 on ClinicalTrials.gov ↗ ← All trials in Canada